[1] 中华医学会妇产科学分会产科学组.乙型肝炎病毒母婴传播预防临床指南. 2015, 18:321-325.
[2] Kar P, Sengupta A.Synthetic therapeutics for the treamtment of hepatitis b during pregnancy. Expert Opin Pharmacother, 2018,19:1771-1778.
[3] Terrault NA,Lok ASF,McMahon BJ,et al.Update on prevention,diagnosisi,and treatment of hepatitis b: AASLD 2018 hepatitis b guidance. Hepatology, 2018, 67:1560-1599.
[4] European association for the study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis b virus infection. Hepatol Int,2017,67:370-398.
[5] 中华医学会肝病学分会,中华医学会感染病学分会.中西医结合肝病杂志,2015,25:384.
[6] 周培,渠淑云. 高载量HBV DNA孕妇阻断方案研究.胃肠病和肝病学杂志, 2017, 26:1428-1431.
[7] Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis b virus infection: significance of maternal viral load and strategies for intervention. J Hepatol, 2013,59:24-30.
[8] YIN Y Z,ZHOU J,ZHANG P Z,et al.Identification of risk factorsrelated to the failure of immunization to interrupt hepatitis b virus perinatal transmission.Zhonghua Gan Zang Bing Za Zhi,2013,21:105-110.
[9] Zou H, Chen Y, Duan Z, Zhang H, et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat,2012,19:e18-e25.
[10] Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis b. Gastroenterology, 2011,140:132-143.
[11] Tsai NC, Marcellin P, Buti M, et al. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis b. Dig Dis Sci, 2015,60:260-268.
[12] Kamkuemah M, Kaplan R, Bekker LG, et al. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa. Trop Med Int Health, 2015,20:518-526. |
